On the risk of delisting of ordinary shares of Korro Bio, Inc. (KRRO)

The International Trading System Limited (hereinafter — ITS) informs on the information concerning delisting risk of ordinary shares of Korro Bio, Inc. (ISIN US5009461089, Shares) from The Nasdaq Stock Market LLC (Nasdaq).

Information on delisting risk of ordinary shares by Nasdaq

On March 18, 2025, Korro Bio, Inc. (the Company) submitted Annual report on Form 10-K to The United States Securities and Exchange Commission. According to the report, the Company has incurred a history of recurring losses, negative cash flows from operations, and the ongoing need for significant additional financing to fund its preclinical and clinical development activities, manufacturing, and potential commercialization efforts, with no assurance that it will be able to secure the necessary funding on acceptable terms or achieve sustained profitability. These conditions led the Company’s management to raise substantial doubt about its ability to continue as a going concern for more than twelve months from the date of these financial statements. For more information, please refer to the report available on the SEC website.

Information regarding possible actions to be taken by ITS

If Nasdaq suspends trading in the Company’s ordinary shares, ITS will prohibit submission of orders and will restrict ability to conclude agreements in respect of the Company’s ordinary shares. If the Company’s ordinary shares are delisted from Nasdaq, ITS will terminate trading in the Company’s ordinary shares. However, in case the Company’s ordinary shares become listed, or admitted to trading on another Recognised Trading Venue, ITS will consider but does not guarantee continuation of trading in the Company’s ordinary shares.